Advances in epilepsy: New perspectives on new-onset epilepsy, comorbidities, and pharmacotherapy

F1000 Medicine Reports

Volumn 2, Issue 1, 2010, Pages

  Kanner, Andres M ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ENZYME INDUCING AGENT; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED RELEASE FORMULATION; DEPRESSION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEIZURE; SUICIDAL IDEATION; SYMPTOMATIC EPILEPSY; TERATOGENICITY; THERAPY EFFECT; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT;

EID: 77955066678     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M2-51     Document Type: Review

References (24)

1. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J Jr: Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-2. (Pubitemid 40470667)
2. Hesdorffer DC, Benn EK, Cascino GD, Hauser WA: Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009, 50:1102-8.
3. Taylor J, Kolamunnage-Dona R, Marson AG, Smith PE, Aldenkamp AP, Baker GA; SANAD study group: Patients with epilepsy: cognitively compromised before the start of antiepileptic drug treatment? Epilepsia 2009, 51:48-56.
4. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S: Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-44.
5. Christensen J, Vestergaard M, Mortensen P, Sidenius P, Agerbo E: Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007, 6:693-8. (Pubitemid 47058376)
6. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ: Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007, 75:192-6.
7. Kanner AM, Byrne R, Chicharro A, Wuu J, Frey M: A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009, 72:793-9.
8. st Annual Meeting of the American Academy of Neurology: 25 April - 02 May 2009; Seattle, Washington, USA.
9. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Biostatistics: Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. [http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1- 01-FDA.pdf]
10. Hesdorffer DC, Kanner AM: The FDA alert on suicidality and antiepileptic drugs: fire or false alarm? Epilepsia 2009, 50:978-86.
11. Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, Sperling MR: Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009, 65:448-56.
12. Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E: Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008, 70:1586-93.
13. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group: Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-605.
14. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C; American Academy of Neurology; American Epilepsy Society: Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50:1237-46.
15. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, Wyszynski DF: Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008, 70:2152-8.
16. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT; EUROCAT Antiepileptic Drug Working Group: Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008, 71:714-22.
17. Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Allen Hauser W, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C; American Academy of Neurology; American Epilepsy Society: Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50:1229-36.
18. Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, Newman M, Stowe ZN: Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008, 70:2130-6.
19. Longo B, Forinash AB, Murphy JA: Levetiracetam use in pregnancy. Ann Pharmacother 2009, 43:1692-5.
20. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group: Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-9.
21. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J; N166 Levetiracetam Study Group: Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-16.
22. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group: Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-8.
23. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group: The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-15.
24. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR; SANAD Study group: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-26.